I recently finished a brief first-level drug trial at the University of
Kansas Medical Center for Remacemide. Remacemide hydrochloride (RH) belongs
to a new class of drugs that has not been studied in PD. RH may decrease some
of the brain chemicals that cause motor fluctuation.
I received my first study tablets on Dec. 15, 1997. I took 5 tablets twice
a day, approx. 12 hours apart. It was the typical double blind study where
neither the KU staff nor myself were informed whether I received RH or
placeboes, and if RH at what dose. I surmised that 1 of the 5 pills was
probably RH as it had a somewhat bitter taste whereas the other 4 pills were
quite bland. I finished taking study pills after the morning dose on Feb. 2.
I do feel I benefitted from this drug. One reason is the "spunky" factor--
others were commenting on how "spunky" I seemed! Another reason is I think my
periods of dyskinesias grew shorter and less disabling--at least, since going
off of RH, I have had worse bouts.
What is the future of this drug? The level one study is expected to be
wrapped up within six months to a year, and a decision made whether to go to a
broader level two study. KU staff were optimistic that that was likely.
As for myself, KU staff think I may benefit from Tolcapone/Tasmar about which
I inquired, and I am anxiously awaiting its arrival at my pharmacy!
Note to Brian: I think your recent posting re: taking a lesser dose of
(sinemet or its European equivalent) when going forth to an event or situation
that may pump up the adrenaline too is worth a try (if I can resist the habit
of taking a full dose).
Regards to all,
Barb
Barbara Blake-Krebs (57, dx 1984) [log in to unmask]
Merriam, KS, USA (ltr after F is cap "i")
